Abstract
Candida albicans is yeast that is most often associated with serious fungal infections and can cause fungal diseases in immuno-compromised patients especially patients suffering from AIDS, cancer and cases of organ transplant. Amongst women, candidal vaginitis is predominantly caused by strains of Candida albicans and also remains to be a common problem in immuno-competent or healthy women. A study was undertaken to assess the efficacy of a compound CIM 1166 obtained from plant source which was found to possess promising antimicrobial property under in vitro conditions especially against C. albicans. Taking the lead further, a small animal model utilizing aged Swiss albino females that had parturated at least three times were taken up for model development. Infection (7 × 106 cfu/ml) was instilled into the vagina in a volume of 20 μl for 3 days. Vaginal washings were aseptically collected on day 4th to confirm the establishment of infection following which the treatment was started which continued for the next 5 days through vaginal route. Vaginal washings were collected on 6th day and the colony forming units were enumerated on chloramphenicol incorporated SDA plates. The results indicated that there was a significant decrease in the colony forming units in vaginal washings (8.0 × 102 cfu/ml) of the treated animals as compared to blank control group (6.0 × 104 cfu/ml). The positive control group administered with clotrimazole also showed a recovery from infection with a fungal load of 8.78 × 102 cfu/ml. The study proves the efficacy of CIM 1166 in curing vaginal candidiasis in mice, which can be taken up for formulation development and further studies.
References
Calderon R, Williams M, Martinez M, Clemons KV, Stevens DA (2003) Genetic susceptibility of vaginal candidiasis. Med Mycol 41:143–147. doi:10.1080/714043910
Challacombe SJ (1994) Immunologic aspects of oral candidiasis. Oral Surgery. Oral Med Oral Path 78:202–210. doi:10.1016/0030-4220(94)90148-1
Haefner HK (1999) Current evaluation and management of vulvovaginitis. Clin Obstet Gynecol 42:184–195. doi:10.1097/00003081-199906000-00004
Horowithz BJ (1991) Mycotic vulvovaginitis: a broad overview. Am J Obstet Gynecol 165:1188–1192
Khanuja SPS, Chaturvedi P, Agarwal KK, Ahmed A, Kumar TRS, Darokar MP et al (2003) A use of treatment for fungal infections with a synergistic formulation of antifungal agents. US Patent 6,660,761, 9 Dec 2003
MacNeill C, Carey JC (2001) Recurrent vulvovaginal candidiasis. Curr Womens Health Rep 1:31–35
March A (2000) Bacterial vaginosis: a threat to reproductive health? Historical perspectives, current knowledge controversies and research demands. Eur J Contracep Health Care 5:208–219. doi:10.1080/13625180008500398
Odds F (1988) Candidasis of oropharynx. In: Odds F (ed) Candida and candidiasis: a review and bibliography, 2nd edn. W. B. Saunder’s, London, UK, pp 117–123
Sawyer PR, Brogden RN, Pinder RM, Speight TM, Avery (1975) Clotrimazole: a review of its antifungal activity and therapeutic efficacy. Drugs 9:424–447. doi:10.2165/00003495-197509060-00003
Sobel J (1992) Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infec Dis 14(Suppl 1):S148
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dhawan, S., Pal, A., Ancha, R. et al. Efficacy of CIM 1166, a combination of compounds derived from Mentha spp. in alleviating experimental vulvovaginal candidiasis in mice. World J Microbiol Biotechnol 25, 161–163 (2009). https://doi.org/10.1007/s11274-008-9871-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11274-008-9871-7